Tevis Investment Management Has $1.31 Million Stake in Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Aug 1st, 2023

Tevis Investment Management grew its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 25.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,468 shares of the company’s stock after purchasing an additional 1,691 shares during the period. Johnson & Johnson comprises 1.3% of Tevis Investment Management’s portfolio, making the stock its 26th largest holding. Tevis Investment Management’s holdings in Johnson & Johnson were worth $1,313,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. GW&K Investment Management LLC bought a new stake in Johnson & Johnson during the fourth quarter worth approximately $35,000. Dark Forest Capital Management LP increased its stake in shares of Johnson & Johnson by 1,044.4% in the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock valued at $36,000 after buying an additional 188 shares in the last quarter. Ruedi Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at $42,000. Kepos Capital LP acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at $45,000. Finally, VitalStone Financial LLC bought a new position in Johnson & Johnson in the fourth quarter valued at about $52,000. Institutional investors own 67.57% of the company’s stock.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of the stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the transaction, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the transaction, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the transaction, the executive vice president now owns 65,934 shares of the company’s stock, valued at $10,549,440. The disclosure for this sale can be found here. Insiders have sold 47,163 shares of company stock valued at $7,928,856 over the last ninety days. 0.20% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Performance

JNJ opened at $167.53 on Tuesday. The firm has a market cap of $435.37 billion, a P/E ratio of 33.91, a price-to-earnings-growth ratio of 2.93 and a beta of 0.55. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $181.04. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07. The business’s fifty day moving average is $161.97 and its 200-day moving average is $161.07.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.62 by $0.18. The company had revenue of $25.53 billion for the quarter, compared to analyst estimates of $24.63 billion. Johnson & Johnson had a return on equity of 37.01% and a net margin of 13.35%. Johnson & Johnson’s quarterly revenue was up 6.3% on a year-over-year basis. During the same period in the prior year, the firm posted $2.59 EPS. Sell-side analysts expect that Johnson & Johnson will post 10.76 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be paid a $1.19 dividend. This represents a $4.76 annualized dividend and a yield of 2.84%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on JNJ shares. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Monday. Barclays lifted their target price on Johnson & Johnson from $171.00 to $175.00 and gave the company an “equal weight” rating in a research report on Monday, July 24th. StockNews.com began coverage on Johnson & Johnson in a research report on Thursday, May 18th. They set a “strong-buy” rating on the stock. TheStreet cut Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, May 19th. Finally, Raymond James upped their price objective on Johnson & Johnson from $181.00 to $184.00 and gave the stock an “outperform” rating in a research note on Monday, July 24th. Eight equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Hold” and an average target price of $171.60.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.